中国医院用药评价与分析2024，Vol.24Issue(7)：774-777,782,5.DOI:10.14009/j.issn.1672-2124.2024.07.002
非小细胞肺癌EGFR基因少见突变P733L对第1代和第3代EGFR-TKI敏感性的研究
Sensitivity of EGFR P733L Rare Mutation to the First-and Third-Generation EGFR-TKIs in Non-Small Cell Lung Cancer
摘要
Abstract
OBJECTIVE:To analyze the sensitivity of epidermal growth factor receptor(EGFR)P733L rare mutation to the first-and third-generation EGFR-tyrosine kinase inhibitor(TKIs)in non-small cell lung cancer.METHODS:Sensitivity of EGFR L858R and P733L to the first-and third-generation EGFR-TKIs was analyzed by MTT and clone formation experiments.Inhibition effect of the first-and third-generation EGFR-TKIs on the migration of EGFR L858R and P733L lung cancer cells was analyzed by Transwell assay.Role of the first-and third-generation EGFR-TKIs in promoting apoptosis of EGFR L858R and P733L lung cancer cells was analyzed by the detection of apoptosis proteins.RESULTS:The first-and third-generation EGFR-TKIs inhibited the cell proliferation,clone formation,and cell migration of EGFR L858R and P733L.Compared with the wild-type EGFR lung cancer cells,the EGFR kinase activity of EGFR L858R and P733L cells was inhibited and cell apoptosis increased significantly after the first-and third-generation EGFR-TKIs treatment.CONCLUSIONS:The sensitivity of EGFR P733L mutant cells to the first-and third-generation EGFR-TKIs is similar to that of EGFR L858R mutant cells,which provides experimental evidence for the benefit of rare mutations in EGFR gene from EGFR-TKIs treatment.关键词
非小细胞肺癌/表皮生长因子受体酪氨酸激酶抑制剂/EGFR少见突变/EGFR P733L/药物敏感性Key words
Non-small cell lung cancer/Epidermal growth factor receptor-tyrosine kinase inhibitor/EGFR rare mutation/EGFR P733L/Drug sensitivity分类
医药卫生引用本文复制引用
车娟娟,王婧,甄洪超,林海珊,尚昆,俞静..非小细胞肺癌EGFR基因少见突变P733L对第1代和第3代EGFR-TKI敏感性的研究[J].中国医院用药评价与分析,2024,24(7):774-777,782,5.基金项目
国家自然科学基金面上项目(No.81774221) （No.81774221）
